A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

A new analysis that shows the effect of the diabetes vaccine Diamyd[®] (GAD-alum) in reducing the time a patient has high blood glucose, has been selected to be presented at the ISPAD conference (The International Society of Pediatric and Adolescent Diabetes), which this year will be held on 13-15 October. The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.The analysis shows that individuals with type 1 diabetes who carry the gene HLA DR3-DQ2, 15 months after